Oramed Pharmaceuticals Inc.

26/06/2024

Oramed Letter to Shareholders - https://mailchi.mp/oramed/oramed-letter-to-shareholders-fwwkozy4ih $ORMP

We are pleased to share this letter from the CEO

26/06/2024

Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock - https://mailchi.mp/oramed/oramed-pharmaceuticals-inc-announces-the-buy-back-of-its-common-stock $ORMP

Repurchase plan allowing for the buy-back over the next 12 months

20/02/2024

Oramed Letter to Shareholders - https://mailchi.mp/oramed/oramed-letter-to-shareholders-rle6rx759k We're happy to report that we stand today on solid ground with many opportunities through which we seek to increase shareholder value. $ormp

We're happy to report that we stand today on solid ground with many opportunities through which we seek to increase shareholder value.

23/08/2023

This week we hosted colleagues from HTIT for ongoing discussions on our Joint Venture. We look forward to working together to bring oral insulin to market in China and beyond.

$ORMP

02/08/2023

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Technology Globally - https://mailchi.mp/oramed/oramed-signs-term-sheet-with-htit-to-create-a-joint-venture-to-advance-technology-globally

The JV would be responsible for developing, marketing and commercializing drug products globally, focusing on Oramed’s oral insulin and POD™ technology, as well as other assets in the Oramed pipeline. The parties intend for the JV to initiate a Phase 3 oral insulin trial in the United States.
$ORMP

Joint Venture to advance registration of oral insulin in the United States and other countries

20/06/2023

Oramed to Present at 83rd American Diabetes Association Conference - https://mailchi.mp/oramed/oramed-to-present-at-83rd-american-diabetes-association-conference
The presentation will include an overview of data from Oramed’s Phase 2 oral insulin trial for the treatment of NASH as well as discuss how oral insulin was found to potentially reduce liver fibrosis and fat in patients with NASH and Type 2 Diabetes.
$ORMP

The presentation will include an overview of data from Oramed’s Phase 2 oral insulin trial for the treatment of NASH as well as discuss how oral insulin was found to potentially reduce liver fibrosis and fat in patients with NASH and Type 2 Diabetes.

18/05/2023

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit - https://mailchi.mp/oramed/oramed-to-present-at-novel-therapies-for-type-2-diabetes-obesity-summit
Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Summit in Boston, MA, on May 31, 2023. The presentation will include an overview of Oramed’s oral delivery technology as well as insights from the Company’s recent Phase 3 oral insulin clinical trials.

$ORMP

Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Summit in Boston, MA, on May 31, 2023.

15/05/2023

Oramed announces its Chinese partner successfully completed a Phase 3 oral insulin clinical trial and that Oramed has completed an analysis of its U.S.-based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups - https://mailchi.mp/oramed/oramed-announces-that-its-chinese-partner-successfully-completed-a-phase-3-oral-insulin-clinical-trial
$ORMP

Oramed has completed an analysis of its U.S.-based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups

01/05/2023

Oramed is excited to welcome Ben Shapiro to its Board of Directors.

Ben brings a wealth of experience from across multidisciplinary sectors. Ben Shapiro is a successful entrepreneur and business professional who co-founded The Daily Wire, a successful, industry leading, international media outlet. He is also host of “The Ben Shapiro Show,” a popular podcast, and he is the author of numerous New York Times best-selling books.

“We are excited to welcome Ben onto our Board. Ben’s unique talents and qualifications are expected to bring real value to the current Oramed Board. We are delighted to begin working in earnest with him to build shareholder value,” said Oramed Chief Executive Officer, Nadav Kidron.

​​Mr. Shapiro said, “I believe Oramed is in a unique position to utilize its current capital effectively in ways that will be beneficial to its shareholders, given its skilled management and cash position. I am happy to join Oramed’s Board in what I am sure will be an exciting future for Oramed and its shareholders.”

$ORMP

“We are excited to welcome Ben onto our Board. Ben’s unique talents and qualifications are expected to bring real value to the current Oramed Board. We are delighted to begin working in earnest with him to build shareholder value,” said Oramed Chief Executive Officer, Nadav Kidron.

04/01/2023

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes - https://mailchi.mp/oramed/oramed-granted-us-combination-therapy-patent-for-oral-glp-1-insulin

“With the topline data for our first Phase 3 oral insulin trial expected soon, we continue to further fortify Oramed’s leading position with respect to intellectual property assets addressing the oral delivery of therapeutic proteins currently only available via injection,” stated Oramed CEO Nadav Kidron.
$ORMP

“With the topline data for our first Phase 3 oral insulin trial expected soon, we continue to further fortify Oramed’s leading position with respect to intellectual property assets addressing the oral delivery of therapeutic proteins currently only available via injection,” stated Oramed CEO N...

21/12/2022

Oramed Letter to Shareholders - https://mailchi.mp/oramed/oramed-letter-to-shareholders-nb2kdbc3ar

The year 2022 was a very strong year for Oramed. The first of our two Phase 3 oral insulin trials completed enrollment and we expect to announce topline results in mid-January 2023. We finished Q3 with a cash balance of $160 million, giving us a long runway through topline results for both of our Phase 3 oral insulin trials and filing for U.S. FDA approval of ORMD-0801, potentially the world’s first oral insulin capsule to reach the market.
$ORMP

Topline Pivotal Phase 3 Oral Insulin Data Expected Mid-January 2023

13/12/2022

Check out the highlight video of Oramed’s recent webinar sharing data from its positive phase 2 clinical trial of oral insulin for with a Key Opinion Leader Discussion on the current treatment landscape.

You can see the entire webinar here: https://www.youtube.com/watch?v=YRYwZlojhwg

$ORMP

29/11/2022

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism - https://mailchi.mp/oramed/oramed-announces-publication-of-oral-insulin-study-in-peer-reviewed-journal-diabetes-obesity-and-metabolism-kjtg4hfvcm
The article is titled: "Oral Insulin (ORMD-0801) in Type 2 Diabetes Mellitus: Dose-Finding 12-Week Randomized Placebo-Controlled Study" and can be accessed on Oramed's website under Scientific Articles and Abstracts.
$ORMP

The original article titled: Oral Insulin (ORMD-0801) in Type 2 Diabetes Mellitus: Dose-Finding 12-Week Randomized Placebo-Controlled Study

17/11/2022

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH - https://mailchi.mp/oramed/oramed-announces-additional-positive-safety-and-efficacy-data-from-its-phase-2-clinical-trial-of-ormd-0801-for-nash
The presentation of this new data, including a discussion by key opinion leaders, was featured in a webinar today with a replay available on Oramed’s website under Events and Presentations.

$ORMP

Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat, liver stiffness and lipids

17/11/2022

Join us in half an hour

Please join us tomorrow for a highlighting data from our clinical trial of oral insulin for NASH

Register here: https://touchconference.zoom.us/webinar/register/WN_dy3jzksKQA6kBKZdT5a0_g

$ORMP

16/11/2022

Please join us tomorrow for a highlighting data from our clinical trial of oral insulin for NASH

Register here: https://touchconference.zoom.us/webinar/register/WN_dy3jzksKQA6kBKZdT5a0_g

$ORMP

14/11/2022

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea - https://mailchi.mp/oramed/oramed-signs-definitive-deal-with-medicox-to-commercialize-oral-insulin-in-south-korea

“This collaboration offers Oramed a great opportunity to participate in the large and growing Korean market and leverages the commercialization strength of our partner, while allowing Oramed to focus on other key markets, including the United States,” stated Oramed Chief Executive Officer Nadav Kidron.

$ORMP

Large Market Potential: 1 in 7 Koreans Over Age 30 Has Diabetes

10/11/2022

Oramed Reports Third Quarter 2022 Financial Results - https://mailchi.mp/oramed/oramed-reports-third-quarter-2022-financial-results

"We had a strong quarter filled with important milestones. Over the next few months, we look forward to sharing multiple milestones, most notably topline data from our first Phase 3 oral insulin trial expected in January," said Oramed CEO, Nadav Kidron. "Oramed remains in a strong financial position with approximately $160 million in cash and investments as of 09-30-22, allowing us to continue advancing all aspects of our pipeline."

Oramed remains in a strong financial position with approximately $160 million in cash and investments as of September 30, 2022.

09/11/2022

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH with Key Opinion Leader Discussion on Current Treatment Landscape - https://mailchi.mp/oramed/oramed-to-host-webinar-highlighting-detailed-data-from-positive-phase-2-nash-trial

To register for the event, please click the following link: https://touchconference.zoom.us/webinar/register/WN_dy3jzksKQA6kBKZdT5a0_g

$ORMP

Webinar scheduled for Thursday, November 17, 2022, at 11:00 a.m. EST

03/11/2022

November is Diabetes Awareness Month.

At Oramed Pharmaceuticals Inc. we continue to work to bring oral insulin to fruition and look forward to sharing our topline Phase 3 data for oral insulin for the treatment of type 2 diabetes in January. 100 years after the discovery of insulin, a new revolution in diabetes care may be on the horizon.
https://youtu.be/ORqsnxxcyBY

$ORMP

100 years ago insulin was discovered, saving countless lives. Today, Oramed Pharmaceuticals is revolutionizing diabetes care with the development of oral ins...

07/10/2022

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine - https://mailchi.mp/oramed/oramed-subsidiary-oravax-reports-positive-preliminary-phase-1-data-for-its-oral-covid-19-vaccine

“We’re very encouraged by this initial data, which indicates that our platform can be safely and successfully used to orally deliver protein-based vaccines,” said Nadav Kidron, Chairman of Oravax and CEO of Oramed Pharmaceuticals.
$ORMP

Primary and secondary endpoints of safety and immunogenicity met

13/09/2022

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial - https://mailchi.mp/oramed/oramed-reports-positive-top-line-results-from-phase-2-nash-trial

Both the primary and secondary endpoints were met providing strong evidence for the treatment of NASH using Oramed’s oral insulin.

“These results paint an exciting picture for the potential of our oral insulin candidate to treat patients with both diabetes and NASH, a very serious condition with few treatment options,” said Oramed’s Chief Executive Officer, Nadav Kidron.

$ORMP

Primary and secondary endpoint met: ORMD-0801 was safe and well tolerated and showed clinically meaningful reduction of liver fat from baseline at 12 weeks

06/09/2022

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference - https://mailchi.mp/oramed/oramed-to-present-at-hc-wainwright-24th-annual-global-investment-conference

Presentation Details:

Date: Tuesday, September 13, 2022
Time: 3:00 p.m. E.T.
Location: Lotte New York Palace, New York, NY

The presentation will be viewable starting Tuesday, September 13, 2022, at 3:00 p.m. Eastern time, and will be available for 90 days, through the following link: https://journey.ct.events/view/fbd3fb46-d695-4516-9e06-8d9247a157ab

$ORMP

The presentation will be viewable starting Tuesday, September 13, 2022, at 3:00 p.m. ET, through the following link: https://journey.ct.events/view/fbd3fb46-d695-4516-9e06-8d9247a157ab

24/08/2022

ICYMI: Michael Rabinowitz, Oramed’s Chief Commercial Officer, talks to Canaccord Genuity’s Edward Nash about the market potential of Oramed’s oral insulin, currently in Phase 3 trials. Data from the Phase 3 trial is expected in January. Michael also talks about a potential oral insulin NASH treatment currently being studied, with data expected this quarter.

“One in five patients with diabetes needs insulin, so it’s a very sizable population. But as we’ve done market research and talked to thought leaders it’s clear that the opportunity is even bigger. Our profile is very competitive in terms of efficacy and an extremely clean safety and tolerability profile, as we’ve seen in the trials, and we can be positioned very favorably as a second and third-line agent, potentially, depending on the patient journey. The opportunity is just huge.”

You can see the entire presentation here: https://oramed.com/canaccord-genuity-annual-growth-conference/

$ORMP

Oramed will present an in-person company overview and share the Company's latest updates at the Canaccord Genuity Annual Growth Conference, to be held in Boston, Massachusetts from August 8-11, 2022.

11/08/2022

We are pleased to share that yesterday we filed our Q2 2022 Form 10-Q quarterly report. We are in a strong financial position with a robust balance sheet, no debt and approximately $160 million in cash and investments as of June 30, 2022. This position gives us sufficient runway to complete our pivotal oral insulin (ORMD-0801) Phase 3 trials and advance us towards potential FDA approval. Additionally, we will continue investing in our POD™ oral delivery pipeline as well as capitalize on strategic opportunities.

We also have multiple milestones expected over the next several months including topline data expected in January 2023 from our first Phase 3 oral insulin trial and data from our Oravax and NASH trials as well.

We look forward to keeping our shareholders updated on the exciting milestones ahead.

You can see the full filing here: https://oramed.gcs-web.com/static-files/1584208d-cb8c-4733-a5ec-9fef5c27b0c5

Forward-looking statements are subject to the cautionary statement included in our Q2 2022 Form 10-Q.

$ORMP

09/08/2022

Happening tomorrow at 4:30 p.m. E.T: We will be presenting an in-person company overview and share the Company's latest updates at the Canaccord Genuity Annual Growth Conference, held in Boston, Massachusetts.

The presentation will be webcasted. The link to view the presentation can be accessed here: https://oramed.com/canaccord-genuity-annual-growth-conference/

$ORMP

Oramed will present an in-person company overview and share the Company's latest updates at the Canaccord Genuity Annual Growth Conference, to be held in Boston, Massachusetts from August 8-11, 2022.

26/07/2022

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial - https://mailchi.mp/oramed/oramed-reaches-50-enrollment-in-its-second-phase-3-oral-insulin-trial
“We are very pleased as we head into the latter half of enrollment for our ORA-D-013-2 trial, especially after having just completed 100% enrollment in our larger ORA-013-1 trial which randomized a total of 710 patients. Together, these trials are the world’s first Phase 3 oral insulin trials conducted under a U.S. FDA IND,” said Oramed’s Chief Executive Officer, Nadav Kidron.

To be added to the Oramed updates list, register through the following link: https://oramed.com/contact-us/

$ORMP

ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol

18/07/2022

“Almost all my patients would prefer taking a once a day oral than taking any kind of injected therapy. I think this has broad applicability across multiple populations,” said Dr. Anne L. Peters, Keck School of Medicine of USC, in a recent webinar on “The Need for Oral Insulin in Type 2 Diabetes”.

To view the full webinar, click here: https://www.youtube.com/watch?v=yrWtf8PSgk0&t=10s

$ORMP

11/07/2022

Oramed to Present at the Upcoming Canaccord Genuity Conference - https://mailchi.mp/oramed/oramed-to-present-at-the-upcoming-canaccord-genuity-conference

The presentation will include a company overview and the Company’s latest updates. It will be held in Boston, Massachusetts on August 10, 2022 at 4:30 P.M. ET.

The link to view the presentation will be uploaded to the Oramed website (www.oramed.com) 48 hours before the event and will be available for 90 days following the presentation.

$ORMP

The in-person presentation will take place on August 10, 2022 at 4:30p.m. ET.

07/07/2022

Oramed Letter to Shareholders - https://mailchi.mp/oramed/oramed-letter-to-shareholders
As we enter the second half of 2022, we are pleased to share with you updates regarding Oramed Pharmaceuticals and our subsidiary Oravax Medical. Oramed is extremely well positioned in terms of cash position, Phase 3 oral insulin program, IP portfolio and platform technology-which can be used for numerous indications.

$ORMP

As we enter the second half of 2022, we are pleased to share with you updates regarding Oramed Pharmaceuticals and our subsidiary Oravax Medical.